Robert Lande - Knight Therapeutics Independent Director

GUD Stock  CAD 5.49  0.02  0.36%   

Director

Mr. Robert N. Lande is Independent Director of the Company. Mr. Lande is the President of FXCM Group LLC, a brokerage firm providing foreign exchange trading services through its electronic platform to clients globally. Formerly, he was Chief Financial Officer of Global Brokerage Inc., a shareholder in FXCM Group LLC. Previously, Mr. Lande was Managing Partner and Chief Operating Officer of Riveredge Capital Partners LLC and prior to that worked for over 16 years within the BCEBell Canada group where his last position was Chief Financial Officer of Telecom Amricas Ltd., a joint venture between Bell Canada International, ATT and America Movil. Mr. Lande is a Chartered Financial Analyst and holds an M.B.A. from the John Molson School of Business and a B.A. in Economics from McGill University. Mr. Lande was a director of Paladin from 1995 to 2014. since 2013.
Age 53
Tenure 12 years
Professional MarksMBA
Address 3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8
Phone514 484 4483
Webhttps://www.knighttx.com
Lande was on the Board of Paladin Labs from 1995 to 2014.

Similar Executives

Showing other executives

DIRECTOR Age

Simon PelletierStella Jones
52
David MorrisECN Capital Corp
64
Rubin McDougalElement Fleet Management
62
George BunzeStella Jones
74
Pierre LortieECN Capital Corp
72
Paul StoyanECN Capital Corp
60
Ilkka SuominenWinpak
N/A
Robert CourteauRichelieu Hardware
N/A
Pierre PomerleauRichelieu Hardware
N/A
Marc PoulinRichelieu Hardware
52
Karen MartinECN Capital Corp
54
Robert CoallierStella Jones
58
Karen LaflammeStella Jones
56
James ManziStella Jones
69
Mary WebsterStella Jones
65
Dayna SpiringWinpak
N/A
Paul DampElement Fleet Management
63
Mathieu GauvinRichelieu Hardware
N/A
Andrew ClarkeElement Fleet Management
48
Rocco ColellaElement Fleet Management
N/A
Andrea RosenElement Fleet Management
64
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. Knight Therapeutics (GUD) is traded on Toronto Exchange in Canada and employs 725 people.

Knight Therapeutics Leadership Team

Elected by the shareholders, the Knight Therapeutics' board of directors comprises two types of representatives: Knight Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Knight. The board's role is to monitor Knight Therapeutics' management team and ensure that shareholders' interests are well served. Knight Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Knight Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
BA BA, Ex Chairman
Monica Percario, Global Affairs
Jonathan Goodman, Chief Executive Officer, Director
Robert Lande, Independent Director
Samira Sakhia, President, Chief Financial Officer, Director
BA LLB, Executive Chairman
Michael Tremblay, Independent Director
Susan Emblem, Global Resources
Nancy Harrison, Independent Director
Sylvie Tendler, Independent Director
Stephani Saverio, Vice Development
Meir Jakobsohn, Director
Henrique Dias, Global Marketing
Jeff Martens, Global Commercial
James Gale, Independent Chairman of the Board
Arvind Utchanah, Chief Financial Officer
Leopoldo Bosano, VicePresident Operations
Jody Engel, Senior Director - Business Development
Amal Khouri, Vice President - Business Development
Janice Murray, Independent Director
Nicolas Sujoy, Independent Director
Daniela Marino, Global Compliance
Melanie Groleau, Global Clinical

Knight Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Knight Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Knight Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Knight Stock

  0.74ASM Avino Silver GoldPairCorr

Moving against Knight Stock

  0.7VCM Vecima NetworksPairCorr
  0.56NXE NexGen Energy Earnings Call This WeekPairCorr
  0.35NBLC Nobel29 Resources CorpPairCorr
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Knight Stock

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.